RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
12.04 USD   +7.40%
08/11Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating
MT
08/09RECURSION PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/09RECURSION PHARMACEUTICALS : Provides Business Updates and Reports Second Quarter 2022 Financial Results - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RECURSION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

05/10/2022 | 04:43pm EDT

Item 2.02. Results of Operations and Financial Condition.

On May 10, 2022, Recursion Pharmaceuticals, Inc. issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure. On May 10, 2022, Recursion Pharmaceuticals, Inc. released an updated investor presentation. The investor presentation will be used from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.2.

The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibit 99.2) on this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number              Description
                              Press release issued by Recursion Pharmaceuticals, Inc. dated     May
99.1                            10    , 202    2
                              Investor presentation of Recursion Pharmaceuticals, Inc. dated May 10,
99.2                        2022
                            Cover Page Interactive Data File (embedded within the Inline XBRL
104                         document)

© Edgar Online, source Glimpses

All news about RECURSION PHARMACEUTICALS, INC.
08/11Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neut..
MT
08/09RECURSION PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/09RECURSION PHARMACEUTICALS : Provides Business Updates and Reports Second Quarter 2022 Fina..
PU
08/09RECURSION PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
08/09RECURSION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
08/09Earnings Flash (RXRX) RECURSION Reports Q2 Revenue $7.7M
MT
08/09Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
PR
08/09Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six..
CI
08/02Recursion to Participate in Upcoming Investor Conference
PR
07/21Recursion Pharmaceuticals Obtains European Orphan-Drug Designation for Tumor Syndrome T..
MT
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 46,9 M - -
Net income 2022 -223 M - -
Net cash 2022 252 M - -
P/E ratio 2022 -7,82x
Yield 2022 -
Capitalization 2 084 M 2 084 M -
EV / Sales 2022 39,0x
EV / Sales 2023 30,7x
Nbr of Employees 400
Free-Float 84,1%
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 12,04 $
Average target price 16,20 $
Spread / Average Target 34,6%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-29.71%2 084
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968